Novabay Pharmaceuticals (NBY:NYSE) Annual Reports & Investor Relations Material

Overview

NovaBay Pharmaceuticals, Inc. is a leading pharmaceutical company with a diverse range of product offerings in the eyecare, skincare, and wound care space. Operating both domestically and internationally, the company's flagship product is the Avenova Spray, a cutting-edge solution that removes foreign materials including microbes and debris from the skin surrounding the eyes. NovaBay Pharmaceuticals also offers a range of wound care products that are used in surgical procedures and to treat injuries like ulcers and burns, among others, under the well-known NeutroPhase and PhaseOne brands. The company is dedicated to addressing skincare concerns such as rosacea, acne, and keratosis pilaris, and offers a suite of dermatological solutions under the DERMAdoctor brand. Products are available online and through a variety of retailers and digital beauty outlets. NovaBay Pharmaceuticals, Inc., which was originally known as NovaCal Pharmaceuticals, was founded in 2000 and is located in Emeryville, California.

Frequently Asked Questions

What is Novabay Pharmaceuticals's ticker?

Novabay Pharmaceuticals's ticker is NBY

What exchange is Novabay Pharmaceuticals traded on?

The company's shares trade on the NYSE stock exchange

Where are Novabay Pharmaceuticals's headquarters?

They are based in Emeryville, California

How many employees does Novabay Pharmaceuticals have?

There are 51-200 employees working at Novabay Pharmaceuticals

What is Novabay Pharmaceuticals's website?

It is novabay.com

What type of sector is Novabay Pharmaceuticals?

Novabay Pharmaceuticals is in the Healthcare sector

What type of industry is Novabay Pharmaceuticals?

Novabay Pharmaceuticals is in the Biotechnology industry

Who are Novabay Pharmaceuticals's peers and competitors?

The following five companies are Novabay Pharmaceuticals's industry peers:

- Curis Inc

- Blueprint Medicines

- Tonix Pharmaceuticals Holding Corp.

- Selecta Biosciences

- Idera Pharmaceuticals, Inc.